The evaluation of the ligand for CTLA-4—CD86 molecules showed that in patients with CLL EBV(+) the percentage of CD19+/CD86+ lymphocytes significantly exceeded the values shown in EBV(−) patients and healthy people. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.